These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 36480802)
1. Implementation and Evaluation of a Collaborative, Pharmacy-Based Hepatitis C and HIV Screening Program. Klepser DG; Klepser ME; Peters PJ; Hoover KW; Weidle PJ Prev Chronic Dis; 2022 Dec; 19():E83. PubMed ID: 36480802 [TBL] [Abstract][Full Text] [Related]
2. Innovating the Model for Student Pharmacists to Increase Access to Hepatitis C Testing (Project IMPACT). Januszka J; Notarianni V; Devenny E; Harris E J Am Pharm Assoc (2003); 2023; 63(4):1217-1221. PubMed ID: 37037394 [TBL] [Abstract][Full Text] [Related]
3. Pharmacist-initiated hepatitis C virus screening in a community pharmacy to increase awareness and link to care at the medical center. Isho NY; Kachlic MD; Marcelo JC; Martin MT J Am Pharm Assoc (2003); 2017; 57(3S):S259-S264. PubMed ID: 28506379 [TBL] [Abstract][Full Text] [Related]
4. Pharmacists performing hepatitis C antibody point-of-care screening in a community pharmacy: A pilot project. Dong BJ; Lopez M; Cocohoba J J Am Pharm Assoc (2003); 2017; 57(4):510-515.e2. PubMed ID: 28602784 [TBL] [Abstract][Full Text] [Related]
5. Time and motion study of hepatitis C virus point-of-care testing in community pharmacies. Beuschel T; Gootee E; Jordan M; Sikkenga T; Klepser DG; Holmquist H; de Voest A; Klepser ME J Am Pharm Assoc (2003); 2023; 63(1):435-439. PubMed ID: 36463010 [TBL] [Abstract][Full Text] [Related]
6. Patient awareness, willingness, and barriers to point-of-care hepatitis C screening in community pharmacy. Brewer A; Hanna C; Eckmann L; Schadler A; Divine H J Am Pharm Assoc (2003); 2018; 58(4S):S69-S72.e1. PubMed ID: 30006188 [TBL] [Abstract][Full Text] [Related]
7. Pharmacist Comfort and Awareness of HIV and HCV Point-of-Care Testing in Community Settings. Min AC; Andres JL; Grover AB; Megherea O Health Promot Pract; 2020 Sep; 21(5):831-837. PubMed ID: 31257939 [TBL] [Abstract][Full Text] [Related]
8. Attitudes toward pharmacy-based HCV/HIV testing among people who use drugs in rural Kentucky. Duong M; Delcher C; Freeman PR; Young AM; Cooper HLF J Rural Health; 2022 Jan; 38(1):93-99. PubMed ID: 33666274 [TBL] [Abstract][Full Text] [Related]
9. Pharmacist-led HIV and hepatitis C point-of-care testing and risk mitigation counseling in individuals experiencing homelessness. Kherghehpoush S; McKeirnan KC Explor Res Clin Soc Pharm; 2021 Mar; 1():100007. PubMed ID: 35479505 [TBL] [Abstract][Full Text] [Related]
10. Expanding access to HIV testing through Canadian community pharmacies: findings from the APPROACH study. Kelly DV; Kielly J; Hughes C; Gahagan J; Asghari S; Hancock S; Burt K; Smyczek P; Charlton C; Nguyen H BMC Public Health; 2020 May; 20(1):639. PubMed ID: 32380978 [TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus screening in community pharmacies: results on feasibility from a Swiss pilot. Stämpfli D; Imfeld-Isenegger TL; Hersberger KE; Messerli M BMC Infect Dis; 2023 Jun; 23(1):384. PubMed ID: 37286975 [TBL] [Abstract][Full Text] [Related]
12. Hepatitis C screening in a community pharmacy setting: Patient perspective. Pegump KN; Nichols RE; Polgreen LA; Veach SR; Crowner AB; Witry MJ J Am Pharm Assoc (2003); 2023; 63(4S):S78-S82. PubMed ID: 36804712 [TBL] [Abstract][Full Text] [Related]
13. HIV testing in community pharmacies and retail clinics: a model to expand access to screening for HIV infection. Weidle PJ; Lecher S; Botts LW; Jones L; Spach DH; Alvarez J; Jones R; Thomas V J Am Pharm Assoc (2003); 2014; 54(5):486-92. PubMed ID: 25216878 [TBL] [Abstract][Full Text] [Related]
14. Feasibility and outcomes of a hepatitis C screening programme in community pharmacies. Gauld N; Perry J; Jackson C; Gane E N Z Med J; 2020 Nov; 133(1525):74-83. PubMed ID: 33223550 [TBL] [Abstract][Full Text] [Related]
16. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial. Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210 [TBL] [Abstract][Full Text] [Related]
17. Pharmacists' Opinions on the Implementation of HIV and HepC Point-of-Care-Testing in a U.S. Pharmacy Chain. So E; Brands M; Suomala E; Ogden B; Riss J; Cernasev A; Schommer J Innov Pharm; 2019; 10(1):. PubMed ID: 34007531 [TBL] [Abstract][Full Text] [Related]
18. The role of community pharmacies in the HIV and HCV care continuum. Kherghehpoush S; McKeirnan KC Explor Res Clin Soc Pharm; 2023 Mar; 9():100215. PubMed ID: 36938123 [TBL] [Abstract][Full Text] [Related]
19. Point-of-care HIV and hepatitis screening in community pharmacies: a quantitative and qualitative study. Figueira I; Teixeira I; Rodrigues AT; Gama A; Dias S Int J Clin Pharm; 2022 Oct; 44(5):1158-1168. PubMed ID: 36098836 [TBL] [Abstract][Full Text] [Related]
20. Viral Hepatitis and Human Immunodeficiency Virus Testing and Linkage to Care for Individuals Enrolled in an Opioid Treatment Program. Rowan SE; Kamis KF; Beum R; Bryan K; Gawenus L; Colon Sanchez D; Hurley H J Infect Dis; 2020 Sep; 222(Suppl 5):S384-S391. PubMed ID: 32877565 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]